CUREMATCH INC has a total of 14 patent applications. It increased the IP activity by 150.0%. Its first patent ever was published in 2017. It filed its patents most often in EPO (European Patent Office), United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and computer technology are ONCOLOGICA UK LTD, ZHENJIANG FIRST PEOPLES HOSPITAL and Oncology Venture ApS.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 3 | |
#2 | United States | 3 | |
#3 | WIPO (World Intellectual Property Organization) | 3 | |
#4 | Canada | 2 | |
#5 | China | 1 | |
#6 | Republic of Korea | 1 | |
#7 | Mexico | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Computer technology | |
#4 | Measurement | |
#5 | IT methods for management |
# | Name | Total Patents |
---|---|---|
#1 | Tsigelny Igor Flint | 9 |
#2 | Kurzrock Razelle | 7 |
#3 | Bush Kevin Toivo | 6 |
#4 | Pham Timothy Viet | 5 |
#5 | Boichard Amelie Clemence | 5 |
#6 | Boichard Amélie Clémence | 4 |
#7 | Boichard Amelie | 3 |
#8 | Tsigelny Igor | 3 |
#9 | Richard Stephane | 3 |
#10 | Kozhenkov Sergey | 3 |
Publication | Filing date | Title |
---|---|---|
US2020362418A1 | Method of prediction of tumor-derived neo-peptide antigenicity and/or immunogenicity using mutational signature patterns | |
WO2019033123A1 | Drug combinations for targeting multiple mutations in cancer | |
EP3510175A1 | Optimizing therapeutic options in personalized medicine |